Schultz K, MacFarland S, Perrino M, Mitchell S, Kamihara J, Nelson A
Clin Cancer Res. 2024; 31(2):234-244.
PMID: 39540884
PMC: 11747828.
DOI: 10.1158/1078-0432.CCR-24-1947.
Song X, Cai H, Peng W, Chen K, Abuduxukuer Z, Zeng Y
Respir Res. 2024; 25(1):57.
PMID: 38267973
PMC: 10809517.
DOI: 10.1186/s12931-024-02685-6.
Sasongko T, Kademane K, Chai Soon Hou S, Jocelyn T, Zabidi-Hussin Z
Cochrane Database Syst Rev. 2023; 7:CD011272.
PMID: 37432030
PMC: 10334695.
DOI: 10.1002/14651858.CD011272.pub3.
Li M, Zhu W, Wang J, Yang X, Li W, Wang G
J Bras Pneumol. 2022; 48(1):e20210337.
PMID: 35293487
PMC: 8964149.
DOI: 10.36416/1806-3756/e20210337.
Nabbout R, Kuchenbuch M, Chiron C, Curatolo P
CNS Drugs. 2021; 35(9):965-983.
PMID: 34417984
DOI: 10.1007/s40263-021-00835-8.
Tuberous sclerosis complex for the pulmonologist.
Rebaine Y, Nasser M, Girerd B, Leroux C, Cottin V
Eur Respir Rev. 2021; 30(161).
PMID: 34348978
PMC: 9488995.
DOI: 10.1183/16000617.0348-2020.
Zoledronic acid inhibits TSC2-null cell tumor growth via RhoA/YAP signaling pathway in mouse models of lymphangioleiomyomatosis.
Zhao D, Wu J, Zhao Y, Shao W, Cheng Q, Shao X
Cancer Cell Int. 2020; 20:46.
PMID: 32063747
PMC: 7011352.
DOI: 10.1186/s12935-020-1131-4.
Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study.
Kim C, Do K, Cha J, Song J, Lee S, Lee K
Eur Radiol. 2019; 30(2):735-743.
PMID: 31471750
DOI: 10.1007/s00330-019-06412-4.
The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth.
Amin S, Lux A, OCallaghan F
Br J Clin Pharmacol. 2018; 85(1):37-46.
PMID: 30290005
PMC: 6303203.
DOI: 10.1111/bcp.13780.
The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis.
Gao N, Zhang T, Ji J, Xu K, Tian X
Orphanet J Rare Dis. 2018; 13(1):134.
PMID: 30107845
PMC: 6092843.
DOI: 10.1186/s13023-018-0874-7.
Pulmonary lymphangioleiomyomatosis presenting as spontaneous pneumothorax treated with sirolimus - A case report.
Verma A, Joshi A, Mishra A, Kant S, Singh A
Lung India. 2018; 35(2):154-156.
PMID: 29487252
PMC: 5846266.
DOI: 10.4103/lungindia.lungindia_60_17.
Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V, Dergilev K, Holman K, Parfyonova Y, Tsokolaeva Z, Teter M
J Biol Chem. 2017; 292(50):20528-20543.
PMID: 28972182
PMC: 5733590.
DOI: 10.1074/jbc.M117.799593.
The dual PI3K/mTOR inhibitor GSK2126458 is effective for treating solid renal tumours in mice through suppression of cell proliferation and induction of apoptosis.
Narov K, Yang J, Samsel P, Jones A, Sampson J, Shen M
Oncotarget. 2017; 8(35):58504-58512.
PMID: 28938574
PMC: 5601670.
DOI: 10.18632/oncotarget.17215.
A brain proteomic investigation of rapamycin effects in the mouse model.
Wesseling H, Elgersma Y, Bahn S
Mol Autism. 2017; 8:41.
PMID: 28775826
PMC: 5540199.
DOI: 10.1186/s13229-017-0151-y.
Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.
Palavra F, Robalo C, Reis F
Oxid Med Cell Longev. 2017; 2017:9820181.
PMID: 28386314
PMC: 5366202.
DOI: 10.1155/2017/9820181.
Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2 Mice Is Superior to Everolimus Alone.
Yang J, Samsel P, Narov K, Jones A, Gallacher D, Gallacher J
Neoplasia. 2017; 19(2):112-120.
PMID: 28092822
PMC: 5238457.
DOI: 10.1016/j.neo.2016.12.008.
Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.
McCormack F, Gupta N, Finlay G, Young L, Taveira-DaSilva A, Glasgow C
Am J Respir Crit Care Med. 2016; 194(6):748-61.
PMID: 27628078
PMC: 5803656.
DOI: 10.1164/rccm.201607-1384ST.
The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial.
Randell E, McNamara R, Davies D, Owen-Jones E, Kirby N, Angel L
Trials. 2016; 17:398.
PMID: 27515417
PMC: 4981993.
DOI: 10.1186/s13063-016-1446-6.
Rapamycin and rapalogs for tuberous sclerosis complex.
Sasongko T, Ismail N, Zabidi-Hussin Z
Cochrane Database Syst Rev. 2016; 7:CD011272.
PMID: 27409709
PMC: 6458010.
DOI: 10.1002/14651858.CD011272.pub2.
Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.
Aghighi M, Boe J, Rosenberg J, von Eyben R, Gawande R, Petit P
Radiology. 2016; 280(3):905-15.
PMID: 26982677
PMC: 5006736.
DOI: 10.1148/radiol.2016151301.
